

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-58 (cancelled).

Claim 59 (currently amended).      A substantially purified polypeptide comprising amino acids 58 through 404 of SEQ ID NO:4 or 6, wherein said polypeptide inhibits endothelial cell migration.

Claim 60 (cancelled).

Claim 61 (previously presented).      The polypeptide of claim 59 in non-glycosylated form.

Claim 62 (previously presented).      The polypeptide of claim 59 further comprising a leucine zipper polypeptide.

Claim 63 (previously presented).      The polypeptide of claim 59 further comprising an Fc polypeptide.

Claim 64 (previously presented).      The polypeptide of claim 59 further comprising a peptide linker.

Claim 65 (previously presented).      A composition comprising the polypeptide of claim 59 and a pharmaceutically acceptable carrier.

Claim 66 (currently amended).      A substantially purified polypeptide comprising amino acids 74 through 365 of SEQ ID NO:10, 12, or 31, wherein said polypeptide inhibits endothelial cell migration.

Claim 67 (cancelled).

Claim 68 (previously presented).      The polypeptide of claim 66 in non-glycosylated form.

Claim 69 (previously presented). The polypeptide of claim 66 further comprising a leucine zipper polypeptide.

Claim 70 (previously presented). The polypeptide of claim 66 further comprising an Fc polypeptide.

Claim 71 (previously presented). The polypeptide of claim 66 further comprising a peptide linker.

Claim 72 (previously presented). A composition comprising the polypeptide of claim 66 and a pharmaceutically acceptable carrier.

Claim 73 (previously presented). A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acids 58 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (b) amino acids 74 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (c) amino acids 74 through 404 of SEQ ID NO:4 or 6; and
- (d) amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 74 (previously presented). The polypeptide of claim 73 in non-glycosylated form.

Claim 75 (previously presented). The polypeptide of claim 73 further comprising a leucine zipper polypeptide.

Claim 76 (previously presented). The polypeptide of claim 73 further comprising an Fc polypeptide.

Claim 77 (previously presented). The polypeptide of claim 73 further comprising a peptide linker.

Claim 78 (previously presented). A composition comprising the polypeptide of claim 73 and a pharmaceutically acceptable carrier.

Claims 79-99 (cancelled).

Claim 100 (currently amended). The isolated polypeptide of claims 93 59, 66 or 73 produced by a process comprising:

- (a) culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide; and
- (b) isolating said polypeptide.

Claim 101 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising substantially purifying said polypeptide.

Claim 102 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence is selected from the group consisting of nucleotides 172 to 1026 of SEQ ID NO:3, 5, 9, or 11; nucleotides 172 to 1212 of SEQ ID NO:3 or 5; and nucleotides 172 to 1098 of SEQ ID NO:9 or 11

Claim 103 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO:1, 3, 7, 9, 11, and 30.

Claim 104 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell comprising a polynucleotide having a nucleotide sequence encoding said polypeptide, wherein said nucleotide sequence encodes a polypeptide selected from the group consisting of SEQ ID NO:13, 14, 15, and 16.

Claim 105 (previously presented). The polypeptide of claim 100, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) amino acids 58 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;
- (b) amino acids 58 through 404 of SEQ ID NO:4 or 6;
- (c) amino acids 74 through 342 of SEQ ID NO:4, 6, 10, 12, or 31;

- (d) amino acids 74 through 404 of SEQ ID NO:4 or 6;
- (e) amino acids 58 through 365 of SEQ ID NO:10, 12, or 31; and
- (f) amino acids 74 through 365 of SEQ ID NO:10, 12, or 31.

Claim 106 (previously presented). The polypeptide of claim 100 in non-glycosylated form.

Claim 107 (previously presented). The polypeptide of claim 100 further comprising a leucine zipper polypeptide.

Claim 108 (previously presented). The polypeptide of claim 100 further comprising an Fc polypeptide.

Claim 109 (previously presented). The polypeptide of claim 100 further comprising a peptide linker.

Claim 110 (previously presented). A composition comprising the polypeptide of claim 100 and a pharmaceutically acceptable carrier.

Claim 111 (previously presented). The polypeptide of claim 100, wherein said polypeptide is produced by a process comprising culturing a recombinant host cell into which a polynucleotide comprising a nucleotide sequence encoding said polypeptide has been introduced.

Claim 112 (previously presented). A substantially purified polypeptide of claim 59 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 51 – 404 of SEQ ID NOs: 4 or 6;
- (b) amino acid residues 52 – 404 of SEQ ID NOs: 4 or 6;
- (c) amino acid residues 53 – 404 of SEQ ID NOs: 4 or 6;
- (d) amino acid residues 54 – 404 of SEQ ID NOs: 4 or 6;
- (e) amino acid residues 55 – 404 of SEQ ID NOs: 4 or 6;
- (f) amino acid residues 56 – 404 of SEQ ID NOs: 4 or 6;
- (g) amino acid residues 57 – 424 of SEQ ID NOs: 4 or 6;
- (h) amino acid residues 51 – 424 of SEQ ID NOs: 4 or 6;
- (i) amino acid residues 52 – 424 of SEQ ID NOs: 4 or 6;

- (j) amino acid residues 53 – 424 of SEQ ID NOs: 4 or 6;
- (k) amino acid residues 54 – 424 of SEQ ID NOs: 4 or 6;
- (l) amino acid residues 55 – 424 of SEQ ID NOs: 4 or 6;
- (m) amino acid residues 56 – 424 of SEQ ID NOs: 4 or 6;
- (n) amino acid residues 57 – 424 of SEQ ID NOs: 4 or 6;
- (o) amino acid residues 58 – 424 of SEQ ID NOs: 4 or 6;
- (p) amino acid residues 51 – 549 of SEQ ID NOs: 4 or 6;
- (q) amino acid residues 52 – 549 of SEQ ID NOs: 4 or 6;
- (r) amino acid residues 53 – 549 of SEQ ID NOs: 4 or 6;
- (s) amino acid residues 54 – 549 of SEQ ID NOs: 4 or 6;
- (t) amino acid residues 55 – 549 of SEQ ID NOs: 4 or 6;
- (u) amino acid residues 56 – 549 of SEQ ID NOs: 4 or 6;
- (v) amino acid residues 57 – 549 of SEQ ID NOs: 4 or 6; and
- (w) amino acid residues 58 – 549 of SEQ ID NOs: 4 or 6.

Claim 113 (previously presented). A substantially purified polypeptide of claim 59 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) the polypeptide sequence of SEQ ID NO: 2;
- (b) the polypeptide sequence of SEQ ID NO: 13; and
- (c) the polypeptide sequence of SEQ ID NO: 15.

Claim 114 (previously presented). A substantially purified polypeptide of claim 66 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) amino acid residues 51 – 356 of SEQ ID NOs: 10, 12 or 31;
- (b) amino acid residues 52 – 356 of SEQ ID NOs: 10, 12 or 31;
- (c) amino acid residues 53 – 356 of SEQ ID NOs: 10, 12 or 31;
- (d) amino acid residues 54 – 356 of SEQ ID NOs: 10, 12 or 31;
- (e) amino acid residues 55 – 356 of SEQ ID NOs: 10, 12 or 31;
- (f) amino acid residues 56 – 356 of SEQ ID NOs: 10, 12 or 31;
- (g) amino acid residues 57 – 356 of SEQ ID NOs: 10, 12 or 31;
- (h) amino acid residues 58 – 356 of SEQ ID NOs: 10, 12 or 31;
- (i) amino acid residues 51 – 385 of SEQ ID NOs: 10, 12 or 31;
- (j) amino acid residues 52 – 385 of SEQ ID NOs: 10, 12 or 31;
- (k) amino acid residues 53 – 385 of SEQ ID NOs: 10, 12 or 31;

- (l) amino acid residues 54 – 385 of SEQ ID NOs: 10, 12 or 31;
- (m) amino acid residues 55 – 385 of SEQ ID NOs: 10, 12 or 31;
- (n) amino acid residues 56 – 385 of SEQ ID NOs: 10, 12 or 31;
- (o) amino acid residues 57 – 385 of SEQ ID NOs: 10, 12 or 31;
- (p) amino acid residues 58 – 385 of SEQ ID NOs: 10, 12 or 31;
- (q) amino acid residues 51 – 510 of SEQ ID NOs: 10, 12 or 31;
- (r) amino acid residues 52 – 510 of SEQ ID NOs: 10, 12 or 31;
- (s) amino acid residues 53 – 510 of SEQ ID NOs: 10, 12 or 31;
- (t) amino acid residues 54 – 510 of SEQ ID NOs: 10, 12 or 31;
- (u) amino acid residues 55 – 510 of SEQ ID NOs: 10, 12 or 31;
- (v) amino acid residues 56 – 510 of SEQ ID NOs: 10, 12 or 31;
- (w) amino acid residues 57 – 510 of SEQ ID NOs: 10, 12 or 31; and
- (x) amino acid residues 58 – 510 of SEQ ID NOs: 10, 12 or 31.

Claim 115 (previously presented). A substantially purified polypeptide of claim 66 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of:

- (a) the polypeptide sequence of SEQ ID NO: 8;
- (b) the polypeptide sequence of SEQ ID NO: 14; and
- (c) the polypeptide sequence of SEQ ID NO: 16.